Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts in Public Health


Combination vaccines represent a valuable technological innovation in the field of infectious disease prevention and public health, because of their great health and economic value from the individual, societal, and healthcare system perspectives.

In order to increase parents’ and healthcare professionals’ confidence in the vaccination programs and maintain their benefits to society, more information about the benefits of innovative vaccination tools such as combination vaccines is needed.

Purpose of this work is an examination of available hexavalent vaccines, that protect against Diphtheria, Tetanus, Pertussis, Poliomyelitis, Hepatitis B and Haemophilus influenzae type b infections. From the epidemiological updates of vaccine preventable diseases to the vaccine development cycle, from the immunogenicity of antigenic components to the safety and co-administration with other vaccines, several aspects of available hexavalent vaccines are discussed and deepened.

Also a number of practical considerations on schedules, age of employment, strategies for vaccination recovery, vaccination in at-risk births are issued, based on the recommendations of Italian Ministry of Health, Italian Society of Pharmacology (SIF), Italian Society for Pediatrics (SIP), Italian Federation of Family Paediatricians (FIMP) and Italian Society of Hygiene, Preventive Medicine and Public Health (SItI).


Agenzia Italiana del Farmaco. Vaccinazioni come strumento di sanità pubblica: le conclusioni del Consiglio UE. www.aifa.gov.it/content/vaccinazioni-come-strumento-disanit%C3%A0-pubblica-le-conclusioni-del-consiglio-ue.

Skibinski D, Baudner B, Singh M, et al. Combination vaccines. J Global Infectious Diseases 2011;3:63.

Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J 2001;20(Suppl 11):S10-8.

Maman K, Zöllner Y, Greco D, et al. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother 2015;11:2132-41.

Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, et al. New perspectives for hexavalent vaccines. Vaccine 2017. http://dx.doi.org/10.1016/j.vaccine.2017.06.063.

Vidor E, Soubeyrand B. Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. Expert review of vaccines 2016;15:1575-82.

Plotkin S, Robinson J, Cunningham G, et al. The complexity and cost of vaccine manufacturing - an overview. Vaccine 2017;35:4064-71.

Rizzo C, Filia A, Rota MC (ISS Epicentro). Obbligo vaccinale: cos’è e perché è importante. www.epicentro.iss.it/temi/vaccinazioni/ObbligoVaccinale.asp.

Ministero della Salute. Piano Nazionale Prevenzione Vaccinale 2017-2019.

Diphtheria - Annual Epidemiological Report for 2015. https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2015-diphtheria.pdf.

ISS Epicentro. Difterite, aggiornamenti. www.epicentro.iss.it/problemi/difterite/aggiornamenti.asp.

ISS Epicentro. Difterite in Italia. www.epicentro.iss.it/problemi/difterite/DifteriteItalia2017.asp.

Zakikhany K, Neal S, Efstratiou A. Emergence and molecular characterisation of non-toxigenic tox gene- bearing Corynebacterium diphtheriae biovar mitis in the United Kingdom, 2003-2012. Euro Surveill 2014;19:20819.

Monaco M, Mancini F, Ciervo A, et al. La difterite: è ancora una malattia da sorvegliare? Notiziario dell’Istituto Superiore di Sanità 2015:28:3-8.

ECDC. Tetanus, annual epidemiological report for 2015. https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2015-tetanus.pdf.

Epicentro. “I vaccini? Funzionano!”. Settimana europea e mondiale delle vaccinazioni 2017. www.epicentro.iss.it/temi/vaccinazioni/SettimanaVaccinazioni2017.asp.

Filia A, Bella A, Hunolstein C, et al. Tetanus in Italy 2001-2010: a continuing threat in older adults. Vaccine 2014;32:639-44.

Epicentro. Tetano. Aspetti epidemiologici. In Italia. www.epicentro.iss.it/problemi/tetano/EpidItalia.asp.

Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C.Public Health Foundation, 2015.

Haberling DL, Holman RC, Paddock CD, et al. Infant and maternal risk factors for pertussis-related infant mortality in the United States, 1999 to 2004. Pediatr Infect Dis J 2009;28:194-8.

Stefanelli P, Buttinelli G, Vacca P, et al. Severe pertussis infection in infants less than 6 months of age: clinical manifestations and molecular characterization. Hum Vaccin Immunother 2017;13:1073-7.

Berbers GAM, de Greeff SC, Mooi FR. Improving pertussis vaccination. Hum Vaccin 2009;5:497-503.

Fedele G, Carollo M, Palazzo R, et al. Parents as source of pertussis transmission in hospitalized young infants. Infection 2017;45:171-8.

Gabutti G, Rota MC. Pertussis: a review of disease epidemiology worldwide and in Italy. Int J Environ Res Public Health 2012;9:4626-38.

ECDC. Pertussis, annual epidemiological report for 2015. https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2015-pertussis.pdf.

Gabutti G, Azzari C, Bonanni P, et al. Pertussis, current perspectives on epidemiology and prevention. Hum Vaccin Immunother 2015;11:108-17.

Advisory Committee on Immunization Practices (ACIP). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women. MMWR Morb Mortal Wkly Rep 2013;62:131-5.

Bull World Health Organ. Europe to be certified free of polio. PMCID 2002;80:688.

ISS Epicentro. Poliomielite. www.epicentro.iss.it/problemi/polio/aggiornamenti.asp.

Ministero della Salute. Poliomielite. www.salute.gov.it/portale/salute/p1_5.jsp?lingua=italiano&id=117&area=Malattie_infettive.

ISS Epicentro. Vaccini e vaccinazioni. www.epicentro.iss.it/temi/vaccinazioni/ObbligoVaccinaleStoria.asp.

ECDC. Polio, annual epidemiological report ECDC 2016.

Edmunds WJ, Medley GF, Nokes DJ, et al. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993;253:197-201.

Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011;18(Suppl 1):1-16.

Legge 27 maggio 1991, n. 165. Obbligatorietà della vaccinazione contro l’epatite virale B. GU n.127 del 1-6-1991.

ISS Epicentro. Epatite virale - aspetti epidemiologici. www.epicentro.iss.it/problemi/epatite/EpidemiologiaItalia.asp.

AUSL Modena. Epatite B. La malattia. www.ausl.mo.it/flex/cm/pages/ServeBLOB.php/L/IT/IDPagina/8125.

Romanò L, Paladini S, Zanetti A. Twenty years of universal vaccination against Hepatitis B in Italy: achievements and challenges. J Public Health Res 2012;1:126-9.

Epicentro. Epatiti virali. Aspetti epidemiologici, Italia. www.epicentro.iss.it/problemi/epatite/EpidemiologiaItalia.asp.

World Health Organization. Haemophilus influenzae type B. Disease burden. www.emro.who.int/health-topics/haemophilus-influenzae-type-b/disease-burden.html.

Whittaker R, Economopoulou A, Dias J, et al. Epidemiology of invasive Haemophilus influenzae disease, Europe, 2007–2014. Emerg Infect Dis 2017;23:396-404.

Martinelli D, Azzari C, Bonanni P, et al. Impact of Haemophilus influenzae type b conjugate vaccination on hospitalization for invasive disease in children fifteen years after its introduction in Italy. Vaccine 2017;35:6297-6301.

Istituto Superiore Sanità. Dati di sorveglianza delle malattie batteriche invasive aggiornati al 16 novembre 2016. www.iss.it/binary/mabi/cont/Report_MBI_20161116_v11.pdf.

SIF, SITI, SIP, FIMMG, FIMP. I vaccini e le vaccinazioni. www.igienistionline.it/docs/2017/09sif.pdf.

Esposito S, Tagliabue C, Bosis S, et al. Hexavalent vaccines for immunization in paediatric age. Clin Microbiol Infect 2014;20:76-85.

Infanrix hexa, RCP. Disponibile su sito AIFA.

Hexyon, RCP. Disponibile su sito AIFA.

Vaxelis, RCP. Disponibile su sito AIFA.

Vesikari T, Silfverdal S, Jordanov E, et al. A randomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3-, 5- and 11- to 12-month schedule. Pediatr Infect Dis J 2017;36:87-93.

Silfverdal S, Icardi G, Vesikari T, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months. Vaccine 2016;34:3810-6.

Corsello G. La pertosse: una malattia che si sconfigge con adeguate coperture vaccinali. RIAP 2017;3:1-8.

Hviid A, Stellfeld M, Andersen P, et al. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine 2004;22:3530-4.

Thierry-Carstensen B, Dalby T, Stevner M, et al. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults – a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine 2013;31:5178-91.

Pertussis surveillance in Sweden. Nineteen-year report. www.folkhalsomyndigheten.se/contentassets/65ed8f6dbdab4999bc358fcd9b657e77/pertussis-sweden-nineteen-year-report.pdf.

SAGE Working Group. Report on pertussis vaccines. www.who.int/immunization/sage/meetings/2015/ april/1_Pertussis_report_final.pdf.

Plotkin S, Orenstein W, Offit P. Vaccines. 6th ed. Scotland: Elsevier/Saunders 2013.

World Health Organization. WHO position paper on pertussis vaccines 2015. Vaccine 2016;34:1423-5.

American Academy of Pediatrics. Acellular pertussis vaccine: recommendations for use as the initial series in infants and children. Pediatrics 1997;99.

Bialek S, Bower W, Novak R, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth a 15-year follow-up study. Pediatr Infect Dis J 2008;27:881-5.

But DY-K, Lai C-L, Limb W-L, et al. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children. Vaccine 2008;26:6587-91.

European Consensus Group on Hepatitis B immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000;355:561-5.

von Kries R, Kalies H, Schmitt HJ. DTPa(+)/Hib combination vaccines: the German experience. An Pediatr (Barc) 2003;58(Suppl 5):22-6. www.analesdepediatria.org/en/pdf/13048831/S300.

Kalies H, Grote V, Siedler A, et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine 2008;12:2545-52.

CDC Pink Book. Immunology and vaccine-preventable diseases. www.cdc.gov/vaccines/pubs/pinkbook/downloads/genrec.pdf.

CDC Pink Book. General recommendations on immunization. www.cdc.gov/vaccines/pubs/pinkbook/downloads/genrec.pdf.

Immunization Action Coalition. Administering vaccines. www.immunize.org/askexperts/administering-vaccines.asp.

WHO, HIS, EMP, QSS Causality assessment of adverse event following immunization (AEFI): user manual for the revised WHO classification. 2013.

Zepp F, Schmitt H, Cleerbout J, et al. Review of 8 years of experience with Infanrix hexaTM (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009;8:663-78.

Nunes Madhi S. Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert Opin Biol Therapy 2013;13:575-93.

AIFA. Rapporto sulla sorveglianza postmarketing dei vaccine in Italia 2016. www.aifa.gov.it/sites/default/files/Rapporto_Vaccini_2016.pdf.

Gallo G, Mel R, Ros E, et al. Guida alle controindicazioni alle vaccinazioni. 5a ed. Roma: Istituto Superiore di Sanità 2017.

Board Calendario per la Vita. Precisazioni del Board del Calendario per la Vita riguardo alla vaccinazione degli inadempienti all’obbligo vaccinale.

AIFA, Ministero della Salute. Bollettino d’informazione sui farmaci: off-label. 2006.

Gazzetta Ufficiale della Repubblica Italiana. Osservanza delle indicazioni terapeutiche autorizzate. Art. 3 D.Lgs. 17 febbraio 1998, n. 23, convertito, con modificazioni, nella Legge 8 aprile 1998, n. 94.1.

Board Calendario per la Vita. Recuperi vaccinali. Indirizzi procedurali inerenti l’applicazione della Legge 119 del 31 luglio 2017 sull’obbligo vaccinale per l’iscrizione a scuola.

ECDC. Vaccinations to be offered in the absence of documented evidence of prior vaccination. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Infectiousdiseases-of-specific-relevance-to-newly-arrived-migrants-in-EUEEA.pdf.

World Health Organization. Recommendations for interrupted or delayed routine immunization - summary of WHO Position Papers. 2017. www.who.int/immunization/policy/Immunization_routine_table3.pdf.

WHO. Preterm birth. Fact sheet. 2016. www.who.int/mediacentre/factsheets/fs363/en/.

Esposito S, Serra D, Gualtieri L, et al. Vaccines and preterm neonates: why, when and with what. Early Human Development 2009;85:S43-5.

Azzari C, Ricci S, Lippi F, et al. Vaccinazione esavalente: nuove evidenze scientifiche e falsi miti da sfatare. RIAP 2017;3:1-8.

Greenberg D, Feldman S. Vaccine interchangeability. Clin Pediatr 2003;42:93-9.

Kumar G, Padhiar A, Carroll S, et al. Estimating the cost impact of switching from a vial to a pre-filled syringe mode of administration for the DTaA-IPV-Hib ‘5-In-1’ vaccine in infants. Value in Health 2013;16:A345.

Wiedenmayer K, Weiss S, Chattopadhyay C, et al. Simplifying paediatric immunization with a fully liquid DTPHepB-Hib combination vaccine: evidence from a comparative time-motion study in India. Vaccine 2009;27:655-9.

Lafuma A, Mara Y. Comparison of the time to prepare contrast media injection in CT scan exam with prefilled syringes and bottles in 7 European countries. Value in Health 2009;12:A254.

De Coster I, Fournie X, Faure C, et al. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine 2015;33:3976-82.